Triple Receptor Agonist (GLP-1 / GIP / Glucagon) | Fat Loss, Glycaemic Control & Metabolic Research | For Research Use Only

Retatrutide is a potent investigational triple agonist peptide that activates GLP-1, GIP, and glucagon receptors, offering a comprehensive mechanism for advanced research into obesity, type 2 diabetes, and metabolic syndrome.

By simultaneously stimulating these three metabolic pathways, Retatrutide demonstrates superior results in weight reduction, appetite regulation, fat metabolism, and insulin sensitivity, outperforming GLP-1 monotherapies and dual agonists in early studies.

The 10mg size is optimal for initiating low-dose research protocols and dose-response experimentation.

🔍 Key Features

• Triple Receptor Targeting (GLP-1, GIP & Glucagon)

• Promotes Fat Oxidation & Appetite Suppression

• Improves Glucose Regulation & Insulin Action

• Ideal for Obesity, T2DM & Metabolic Disease Models

• Supports Long-Acting Weekly Research Protocols

⚙️ Compound Details

• Peptide Name: Retatrutide

• CAS Number: 2381089-83-2

• Molecular Formula: C₂₀₉H₃₂₉N₅₅O₆₆

• Molecular Weight: ~4717.35 g/mol

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised powder

• Unit Size: 10mg per vial

🧊 Storage & Handling

• Storage (lyophilised): –20°C, in a dry, light-protected environment

• Reconstitution: Reconstitute with sterile bacteriostatic water (1–2ml recommended)

• Post-Reconstitution: Store at 2–8°C and use within 10–14 days

• Avoid: Repeated freeze-thaw cycles and direct sunlight

⚠️ For Research Use Only

Retatrutide – 10mg is supplied strictly for laboratory research use only. It is not approved for human consumption, medical use, or diagnostic procedures.